Previous 10 | Next 10 |
Eton Pharmaceuticals (NASDAQ: ETON ) has entered into a co-promotion agreement with Xellia Pharmaceuticals for the promotion of Biorphen (phenylephrine HCl), an only FDA approved ready-to-use formulation of phenylephrine injection indicated for the treatment of hypotension resulting p...
Xellia’s US-based Hospital Sales Force Will Immediately Begin Promoting Biorphen in Collaboration with Eton Agreement Significantly Expands Biorphen Commercial Footprint and Provides Access to Institutions that Prefer Ready-to-Use Injectable Formulations Biorphen, the Only FDA-app...
In the world of subscribers, own the book ."― Goitsemang Mvula Today, we look at an intriguing ' Tier 3 ' small cap concern. The company just came public last year but has already garnered one FDA approval and has a couple more on the horizon. We take an in-depth look at this nam...
~ Biorphen is the First and Only Ready-to-Use FDA-Approved Injectable Formulation of Phenylephrine ~ ~ Biorphen is Now Available for Order Through Major Wholesalers ~ ~ Biorphen is Eton Pharmaceuticals’ First Commercially Available Product ~ DEER PAR...
Eton Pharmaceuticals, Inc. (ETON) Q3 2019 Earnings Conference Call November 14, 2019 4:30 PM ET Company Participants David Krempa - Vice President, Business Development Sean Brynjelsen - Chief Executive Officer Wilson Troutman - Chief Financial Officer Conference Call Particip...
Eton Pharmaceuticals (NASDAQ: ETON ): Q3 GAAP EPS of -$0.28 misses by $0.03 . More news on: Eton Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Biorphen ® Expected to Launch by End of November Company to Host Conference Call and Webcast Today at 4:30 p.m. ET (3:30 p.m. CT) DEER PARK, Ill., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing ...
DEER PARK, Ill., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced it has entered into a $10 million debt facility with SWK Holdings Corporation. ...
DEER PARK, Ill., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report third quarter 2019 financial and operating results on Thurs...
TrovaGene (NASDAQ: TROV ) +56% on positive response to treatment in phase 1b/2 trial of onvansertib in patients with KRAS-mutated metastatic colorectal cancer. More news on: TrovaGene, Inc., Biogen Inc., Stamps.com Inc., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Eton Pharmaceutcials Inc. Company Name:
ETON Stock Symbol:
NASDAQ Market:
Eton Pharmaceutcials Inc. Website:
- Prescription Drug User Fee Act (PDUFA) target action date is February 28, 2025 - - Product has patent protection through 2043 - DEER PARK, Ill., July 15, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innov...
• Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13 th straight quarter of sequential product sales growth • Acquired PKU GOLIKE®, launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...